WeTrade Group (WETG) Announces $50 Million Sales of Monkeypox Virus Test Kits to Parkway Medical Limited

August 12, 2022 7:24 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

WeTrade Group Inc. ("Wetrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced the Company has entered into a sales agreement (the "Agreement") on August 11, 2022 with Parkway Medical Limited ("Parkway Medical") to sell monkeypox virus test kits and antigen tests for US$50 million.

Pursuant to the Agreement, Parkway Medical agreed to purchase 5 million units of nucleic acid test (RT-LAMP) and 6 million units of antigen tests (Colloidal Golden Technique) for an aggregate amount of US$50 million, and Parkway Medical has paid US$1 million as deposit.

Mr. Pijun Liu, Chief Executive Officer of the Company, commented, "We are excited about the sales of monkeypox virus kits and antigen tests to Parkway Medical after obtaining the exclusive sales channel from Jiqing Biomedical Technology Co. Ltd. It is important for us to be efficient so that we can take the lead to effectively tackle the challenges of the monkeypox outbreak. We are delighted to work with Parkway Medical to provide the test kits and antigen tests to overseas market as we aim to contribute to the prevention and control of the outbreak. With the support of our developed business ecosystem, we are optimistic about the future of Wetrade as it will definitely seize business opportunities and generate strong momentum for our growth."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments, Momentum Movers